A Placebo Controlled,Double-Blind Evaluation of Levamisole in the Reduction of the Frequency,Duration and Severity of Attacks in Children Suffering from Recurrent Upper Respiratory Tract Infections

Abstract

In a double-blind placebo controlled study of levamisole in the treatment of children with recurrent upper respiratory tract infection (URI) eighty-six patients took part. Medication was given once a week, in a single body-weight adjusted dose. The children treated with levamisole had a statistically significantly reduced incidence of episodes of infection which were less severe, less prolonged and required less antibiotics. No side-effects were reported.